Disease Impact and Its Correlation With Disease Activity in Psoriatic Arthritis

Assessment of Disease Impact in Patients With Psoriatic Arthritis and Its Correlation With Disease Activity

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07793773

Enrollment

Registered

2026-08-31

Start date

2026-10-01

Completion date

2027-11-01

Last updated

2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Psoriatic Arthritis

Keywords

PsAID-12, DAPSA, Disease Activity, Patient Reported Outcome Measures, Quality of Life, CASPAR Criteria

Brief summary

Psoriatic arthritis (PsA) is a chronic inflammatory musculoskeletal disorder that causes joint pain, stiffness, skin lesions, and functional disability, significantly affecting patients' quality of life. Patient-reported outcome measures (PROMs) provide essential insights into the impact of disease from the patient's perspective. The Psoriatic Arthritis Impact of Disease-12 (PsAID-12) questionnaire is a validated tool designed to evaluate 12 physical and psychological aspects of disease burden. The main purpose of this cross-sectional study is to evaluate disease impact using the Arabic version of the PsAID-12 questionnaire and to investigate how disease impact correlates with clinical disease activity measured by the Disease Activity in Psoriatic Arthritis (DAPSA) score in adult patients with PsA. Participants will undergo routine clinical and rheumatological evaluations, including joint examinations (tender and swollen joint counts), laboratory tests (complete blood count, inflammatory markers such as ESR and CRP, liver and kidney function tests, and lipid profile), and plain radiography of affected joints (hands, feet, and sacroiliac joints). Patients will also complete the Arabic PsAID-12 questionnaire and patient global and pain assessments. All assessments will take place during a single evaluation visit at Assiut University Hospital.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Patients diagnosed with psoriatic arthritis according to the Classification Criteria for Psoriatic Arthritis (CASPAR) criteria * Age ≥ 18 years * Willingness to participate in the study and provide informed consent

Exclusion criteria

* Patients younger than 18 years of age * Presence of other coexisting autoimmune diseases * Patients with advanced malignancy

Design outcomes

Primary

Measure	Time frame	Description
Disease Impact Score Assessed by the Psoriatic Arthritis Impact of Disease (PsAID-12) Questionnaire	Baseline	The Arabic version of the Psoriatic Arthritis Impact of Disease 12-item (PsAID-12) questionnaire is used to evaluate patient-reported disease impact. It assesses 12 domains: pain, fatigue, skin problems, work and leisure activities, functional capacity, discomfort, sleep disturbance, coping, anxiety/fear, embarrassment/shame, social participation, and depression. Each domain is scored on a numerical rating scale from 0 to 10, weighted, and aggregated into a total score ranging from 0 (no impact/best status) to 10 (extreme impact/worst status). Higher total scores indicate greater negative disease impact.

Outcome results